Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥10 screening criteria and two claseprubart treatment arms, 300mg/2mL Q2W and 300mg/2mL Q4W, vs. placebo anticipated to initiate in 2026 Additionally, new preclinical data highlight potential efficacy benefits of upstream (aC1s) vs. downstream (C5) complement inhibition Virtua ...